Antineoplastické, radiosenzibilizující a radioprotektivní vlastnosti kurkuminu

Stáhnout PDF English version

Autoři: Y. B. Cihan
Působiště autorů: Department of Radiation Oncology, Kayseri City Education and Research Hospital, Kayseri, Turkey
Vyšlo v časopise: Klin Onkol 2021; 34(4): 273-277
Kategorie: Přehled
doi: https://doi.org/10.48095/ccko2021273

Souhrn

Východiska: Kurkumin je látka z kořene kurkumy, která dává pokrmům žlutou barvu a používá se jako koření. V kulturách Dálného východu, zejména v indické a čínské tradiční mediccíně, se používá lokálně/místně i systémově při léčbě nemocí. Kurkumin je přírodní látka, která při předávkování nemá toxické účinky. V různých studiích byly prokázány jeho protizánětlivé, antioxidační, antineoplastický, antivirové, antimikrobiální a antiangiogenní účinky a také vliv na migraci buněk, buněčný cyklus, srážení krevních destiček, apoptózu a hojení ran. V posledních letech se kurkumin používá při radioterapii jako radiosenzibilizátor a radioprotektivum. Ačkoli má nízkou biologickou dostupnost, díky své nízké molekulové hmotnosti a vysoké aktivitě inhibovat růst nádorových buněk a chránit zdravé tkáně před nežádoucími účinky radiace se jeví jako ideální molekula. Cíl: V článku je diskutováno použití kurkuminu v kombinaci s radioterapií z pohledu literatury.

Klíčová slova:

kurkumin – radioterapie – radiosenzibilizátor – radioprotektivum

Zdroje

1. World Health Organization. Cancer. [online]. Available from: http: //www.who.int/mediacentre/factsheets/fs297/en/.

2. Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2017; 57 (13): 2889–2895. doi: 10.1080/10408398.2015.1077195.

3. Hatcher H, Planalp R, Cho J et al. Curcumin from ancient medicie to current clinical trials. Cell Moll Life 2008; 65 (11): 1631–1652. doi: 10.1007/s00018-008-7452-4.

4. Aggarwal BB, Sundaram C, Malani N et al. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007; 595: 1–75. doi: 10.1007/978-0-387-46401-5_1.

5. Farhood B, Mortezaee K, Goradel NH et al. Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy. J Cell Physiol 2019; 234 (5): 5728–5740. doi: 10.1002/jcp.27442.

6. Saghatelyan T, Tananyan A, Janoyan N et al. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: a comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine 2020; 70: 153218. doi: 10.1016/j.phymed.2020.153218.

7. Momtazi-Borojeni AA, Mosafer J, Nikfar B et al. Curcumin in advancing treatment for gynecological cancers with developed drug- and radiotherapy-associated resistance. Rev Physiol Biochem Pharmacol 2019; 176: 107–129. doi: 10.1007/112_2018_11.

8. Delavarian Z, Pakfetrat A, Ghazi A et al. Oral administration of nanomicelle curcumin in the prevention of radiotherapy-induced mucositis in head and neck cancers. Spec Care Dentist 2019; 39 (2): 166–172. doi: 10.1111/scd.12358.

9. Pandey A, Gupta R K, Srivastava R. Curcumin – the yellow magic. Asian Journal of Applied Sciences 2011; 4 (4): 343–354. doi: 10.3923/ajaps.2011.343.354.

10. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41 (13): 1955–1968. doi: 10.1016/j.ejca.2005.05.009.

11. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver international 2009; 29 (10): 1457–1466. doi: 10.1111/j.1478-3231.2009.02086.x.

12. Akram M, Uddin S, Ahmed A et al. Curcuma longa and curcumin: a review article. Rom J Biol Plant Biol 2010; 55 (2): 65–70.

13. Chan MM. Inhibition of tumor necrosis factor by curcumin, phytochemical. Biochemical Pharmacology 1995; 49 (11): 1551–1556. doi: 10.1016/0006-2952 (95) 00 171-u.

14. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidat ion in mice. Drug Metab Dispos 1999; 27 (4): 486–494.

15. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (curcuma longa). J Altern Complement Med 2003; 9 (1): 161–168. doi: 10.1089/107555303321223035.

16. Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules 2014; 19 (12): 20091–20112. doi: 10.3390/molecules191220091.

17. Shoba G, Joy D, Joseph T et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta medica 1998; 64 (4): 353–356. doi: 10.1055/s-2006-957450.

18. Thakam A, Saewan N. Antioxidant activities of curcumin-metal complex. Thai Journal of Agricultural Science 2011; 44 (5): 188–193.

19. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23 (1A): 363–398.

20. Srivastava R, Pandey A, Gupta R. Curcumin – the yellow magic. Asian J Applied Sci 2011; 4 (4): 343–354.

21. Reyes-Gordillo K, Segovia J, Shibayama M et al. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 2007; 1770 (6): 989–996. doi: 10.1016/j.bbagen.2007.02.004.

22. Lukita-Atmadja W, Ito Y, Baker GL et al. Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 2002; 17 (5): 399–403. doi: 10.1097/00024382-200205000-00010.

23. Shahcheraghi SH, Zangui M, Lotfi M et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr Pharm Des 2019; 25 (3): 333–342. doi: 10.2174/1381612825666190313123704.

24. Kawamori T, Lubet R, Steele VE et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Research 1999; 59 (3): 597–601.

25. Panahi Y, Darvishi B, Ghanei M et al. Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on nf-kappaB pathway. Cytokine Growth Factor Rev 2016; 28: 21–29. doi: 10.1016/j.cytogfr.2015.12.004.

26. Lim TG, Lee SY, Huang Z et al. Curcumin suppresses proliferation of colon cancer cells by targeting CDK2. Cancer Prev Res 2014; 7 (4): 466–474. doi: 10.1158/1940-6207.CAPR-13-0387.

27. Piper JT, Singhal SS, Salameh MS et al. Mechanisms of anticarcinogenic properties of curcumin the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int J Biochem Cell Biol 1998; 30 (4): 445–456. doi: 10.1016/s1357-2725 (98) 00015-6.

28. Abuelba H, Cotrutz CE, Stoica BA et al. In vitro evaluation of curcumin effect on breast adenocarcinoma 2D and 3D cell cultures. Rom J Morphol Embryol 2015; 56 (1): 71–76.

29. Lopez LM. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008; 52 (Suppl 1): 103–127. doi: 10.1002/mnfr.200700238.

30. Zunino SJ, Storms DH, Newman JW et al. Oral or parenteral administration of curcumin does not prevent the growth of high risk acute lymphoblastic leukemia cells engrafted into a NOD/SCID mouse model. Int J Oncol 2013; 42 (2): 741–748. doi: 10.3892/ijo.2012. 1734.

31. Prasad C P, Rath G, Mathur S et al. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/b-catenin signaling. Chem Biol Interact 2009; 181 (2): 263–271. doi: 10.1016/j.cbi.2009.06. 012.

32. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995; 95 (1–2): 221–225. doi: 10.1016/0304-3835 (95) 03887-3.

33. Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high risk or pre-malignant lesions. Anticancer Res 2001; 21 (4B): 2895–2900.

34. Dhillon N, Aggarwal BB, Newman RA et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14 (14): 4491–4499. doi: 10.1158/1078-0432.CCR-08-0024.

35. Verma V. Relationship and interactions of curcumin with radiation therapy. World J Clin Oncol 2016; 7 (3): 275–283. doi: 10.5306/wjco.v7.i3.275.

36. Hejazi J, Rastmanesh R, Taleban FA et al. Effect of curcumin supplementation during radiotherapy on oxidative status of patients with prostate cancer: a double blinded, randomized, placebo-controlled study. Nutr Cancer 2016; 68 (1): 77–85. doi: 10.1080/01635581.2016.1115 527.

37. Amini P, Saffar H, Nourani MR et al. Curcumin mitigates radiation-induced lung pneumonitis and fibrosis in rats. Int J Mol Cell Med Fall 2018; 7 (4): 212–219. doi: 10.22088/IJMCM.BUMS.7.4.212.

38. Minafra L, Porcino N, Bravatà V et al. Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells. Sci Rep 2019; 9 (1): 11134. doi: 10.1038/s41598-019-47553-2.PMID: 31366901.

39. Ryan Wolf J, Heckler CE, Guido JJ et al. Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Support Care Cancer 2018; 26 (5): 1543–1552. doi: 10.1007/s00520-017-3957-4.

40. Momtazi-Borojeni AA, Ghasemi F, Hesari A et al. Anti-cancer and radio-sensitizing effects of curcumin in nasopharyngeal carcinoma. Curr Pharm Des 2018; 24 (19): 2121–2128. doi: 10.2174/1381612824666180522105 202.

41. Wang WH, Shen CY, Chien YC et al. Validation of enhancing effects of curcumin on radiotherapy with F98/FGT glioblastoma-bearing rat model. Int J Mol Sci 2020; 21 (12): 4385. doi: 10.3390/ijms21124385.

42. Thresiamma KC, George J, Kuttan R. Protective effect of kurkumin, ellagic acid and bixin on radiation induced toxicity. Indian J Exp Biol 1996; 34 (9): 845–847.

43. Inano H, Onoda M. Radioprotective action of kurkumin extracted from curcuma longa LINN: inhibitory effect on formation of urinary 8-hydroxy-2’-deoxyguanosine, tumorigenesis, but not mortality, induced by gamma-ray irradiation. Int J Radiat Oncol Biol Phys 2020; 53 (3): 735–743. doi: 10.1016/s0360-3016 (02) 027 94-3.

44. Chendil D, Ranga RS, Meigooni D et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23 (8): 1599–1607. doi: 10.1038/sj.onc.1207284.